# SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

> **NCT00879008** · — · COMPLETED · sponsor: **Bayer** · enrollment: 345 (actual)

## Conditions studied

- Chronic Bronchitis

## Interventions

- **DRUG:** Moxifloxacin (Avelox, BAY12-8039)

## Key facts

- **NCT ID:** NCT00879008
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2014-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00879008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00879008, "SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00879008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*